IOBT Earnings Yield vs Pe Ratio Analysis

IOBT Stock

USD 0.95 0.01 1.04%

IO Biotech financial indicator trend analysis is infinitely more than just investigating IO Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether IO Biotech is a good investment. Please check the relationship between IO Biotech Earnings Yield and its Pe Ratio accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IO Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy IOBT Stock please use our How to Invest in IO Biotech guide.

Earnings Yield vs Pe Ratio

Earnings Yield vs Pe Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of IO Biotech Earnings Yield account and Pe Ratio. At this time, the significance of the direction appears to have pay attention.

The correlation between IO Biotech's Earnings Yield and Pe Ratio is -0.91. Overlapping area represents the amount of variation of Earnings Yield that can explain the historical movement of Pe Ratio in the same time period over historical financial statements of IO Biotech, assuming nothing else is changed. The correlation between historical values of IO Biotech's Earnings Yield and Pe Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Earnings Yield of IO Biotech are associated (or correlated) with its Pe Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pe Ratio has no effect on the direction of Earnings Yield i.e., IO Biotech's Earnings Yield and Pe Ratio go up and down completely randomly.

Correlation Coefficient

-0.91

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Earnings Yield

The inverse of the price-to-earnings ratio, representing the percentage of each dollar invested in the stock that was earned by the company.

Pe Ratio

Most indicators from IO Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into IO Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IO Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy IOBT Stock please use our How to Invest in IO Biotech guide.Selling General Administrative is likely to drop to about 15.9 M in 2025. Tax Provision is likely to drop to about 939.4 K in 2025

	2022	2023	2024	2025 (projected)
Interest Expense	302K	3K	3.5K	3.3K
Depreciation And Amortization	540K	215K	193.5K	183.8K

Interest Expense Depreciation And Amortization

IO Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets
Total Assets		-0.77	0.68	0.29	1.0	0.62	0.94	-0.25	-0.99	-0.62	0.87	1.0	0.69	0.59	0.76	1.0	0.59	0.28	-0.86	-0.96	0.92	0.87	-0.95	1.0	-0.25	1.0
Short Long Term Debt Total	-0.77		-0.85	-0.23	-0.76	-0.93	-0.83	0.45	0.76	0.8	-0.83	-0.76	-0.78	-0.74	-0.42	-0.76	-0.33	-0.59	0.66	0.84	-0.8	-0.86	0.71	-0.74	0.45	-0.76
Other Current Liab	0.68	-0.85		0.7	0.68	0.92	0.85	-0.54	-0.66	-0.94	0.92	0.67	0.85	0.92	0.17	0.67	-0.04	0.88	-0.81	-0.84	0.75	0.94	-0.74	0.67	-0.54	0.67
Total Current Liabilities	0.29	-0.23	0.7		0.32	0.45	0.52	-0.42	-0.27	-0.68	0.64	0.29	0.58	0.7	-0.13	0.29	-0.46	0.8	-0.7	-0.49	0.38	0.62	-0.51	0.32	-0.42	0.29
Total Stockholder Equity	1.0	-0.76	0.68	0.32		0.62	0.94	-0.24	-0.99	-0.62	0.88	1.0	0.7	0.59	0.76	1.0	0.58	0.29	-0.87	-0.96	0.93	0.88	-0.96	1.0	-0.24	1.0
Other Liab	0.62	-0.93	0.92	0.45	0.62		0.79	-0.61	-0.6	-0.89	0.84	0.61	0.75	0.82	0.25	0.61	0.11	0.81	-0.67	-0.78	0.77	0.85	-0.65	0.6	-0.61	0.61
Net Tangible Assets	0.94	-0.83	0.85	0.52	0.94	0.79		-0.34	-0.93	-0.76	0.97	0.93	0.78	0.71	0.65	0.93	0.42	0.56	-0.92	-0.99	0.96	0.96	-0.95	0.94	-0.34	0.93
Current Deferred Revenue	-0.25	0.45	-0.54	-0.42	-0.24	-0.61	-0.34		0.12	0.77	-0.47	-0.24	-0.39	-0.76	0.17	-0.24	0.25	-0.61	0.5	0.42	-0.39	-0.45	0.38	-0.23	1.0	-0.24
Net Debt	-0.99	0.76	-0.66	-0.27	-0.99	-0.6	-0.93	0.12		0.55	-0.85	-0.99	-0.67	-0.52	-0.79	-0.99	-0.63	-0.25	0.82	0.94	-0.91	-0.85	0.93	-0.99	0.12	-0.99
Retained Earnings	-0.62	0.8	-0.94	-0.68	-0.62	-0.89	-0.76	0.77	0.55		-0.87	-0.61	-0.85	-0.97	-0.07	-0.61	0.15	-0.85	0.82	0.8	-0.68	-0.89	0.72	-0.61	0.77	-0.61
Accounts Payable	0.87	-0.83	0.92	0.64	0.88	0.84	0.97	-0.47	-0.85	-0.87		0.86	0.88	0.82	0.49	0.86	0.22	0.68	-0.95	-0.97	0.9	0.99	-0.94	0.87	-0.47	0.86
Cash	1.0	-0.76	0.67	0.29	1.0	0.61	0.93	-0.24	-0.99	-0.61	0.86		0.69	0.58	0.76	1.0	0.59	0.27	-0.86	-0.96	0.92	0.86	-0.95	1.0	-0.24	1.0
Non Current Assets Total	0.69	-0.78	0.85	0.58	0.7	0.75	0.78	-0.39	-0.67	-0.85	0.88	0.69		0.77	0.23	0.69	-0.06	0.64	-0.8	-0.8	0.62	0.9	-0.78	0.69	-0.39	0.68
Non Currrent Assets Other	0.59	-0.74	0.92	0.7	0.59	0.82	0.71	-0.76	-0.52	-0.97	0.82	0.58	0.77		-0.02	0.58	-0.19	0.85	-0.79	-0.75	0.64	0.84	-0.67	0.58	-0.76	0.58
Other Assets	0.76	-0.42	0.17	-0.13	0.76	0.25	0.65	0.17	-0.79	-0.07	0.49	0.76	0.23	-0.02		0.76	0.91	-0.2	-0.48	-0.63	0.74	0.44	-0.67	0.77	0.17	0.76
Cash And Short Term Investments	1.0	-0.76	0.67	0.29	1.0	0.61	0.93	-0.24	-0.99	-0.61	0.86	1.0	0.69	0.58	0.76		0.59	0.27	-0.86	-0.96	0.92	0.86	-0.95	1.0	-0.24	1.0
Net Receivables	0.59	-0.33	-0.04	-0.46	0.58	0.11	0.42	0.25	-0.63	0.15	0.22	0.59	-0.06	-0.19	0.91	0.59		-0.4	-0.18	-0.4	0.57	0.19	-0.4	0.58	0.25	0.6
Common Stock Shares Outstanding	0.28	-0.59	0.88	0.8	0.29	0.81	0.56	-0.61	-0.25	-0.85	0.68	0.27	0.64	0.85	-0.2	0.27	-0.4		-0.58	-0.52	0.47	0.69	-0.41	0.27	-0.61	0.27
Non Current Liabilities Total	-0.86	0.66	-0.81	-0.7	-0.87	-0.67	-0.92	0.5	0.82	0.82	-0.95	-0.86	-0.8	-0.79	-0.48	-0.86	-0.18	-0.58		0.94	-0.85	-0.93	0.97	-0.88	0.5	-0.86
Inventory	-0.96	0.84	-0.84	-0.49	-0.96	-0.78	-0.99	0.42	0.94	0.8	-0.97	-0.96	-0.8	-0.75	-0.63	-0.96	-0.4	-0.52	0.94		-0.95	-0.96	0.97	-0.96	0.42	-0.96
Other Current Assets	0.92	-0.8	0.75	0.38	0.93	0.77	0.96	-0.39	-0.91	-0.68	0.9	0.92	0.62	0.64	0.74	0.92	0.57	0.47	-0.85	-0.95		0.88	-0.91	0.92	-0.39	0.92
Other Stockholder Equity	0.87	-0.86	0.94	0.62	0.88	0.85	0.96	-0.45	-0.85	-0.89	0.99	0.86	0.9	0.84	0.44	0.86	0.19	0.69	-0.93	-0.96	0.88		-0.92	0.87	-0.45	0.86
Total Liab	-0.95	0.71	-0.74	-0.51	-0.96	-0.65	-0.95	0.38	0.93	0.72	-0.94	-0.95	-0.78	-0.67	-0.67	-0.95	-0.4	-0.41	0.97	0.97	-0.91	-0.92		-0.96	0.38	-0.95
Net Invested Capital	1.0	-0.74	0.67	0.32	1.0	0.6	0.94	-0.23	-0.99	-0.61	0.87	1.0	0.69	0.58	0.77	1.0	0.58	0.27	-0.88	-0.96	0.92	0.87	-0.96		-0.23	1.0
Short Long Term Debt	-0.25	0.45	-0.54	-0.42	-0.24	-0.61	-0.34	1.0	0.12	0.77	-0.47	-0.24	-0.39	-0.76	0.17	-0.24	0.25	-0.61	0.5	0.42	-0.39	-0.45	0.38	-0.23		-0.24
Total Current Assets	1.0	-0.76	0.67	0.29	1.0	0.61	0.93	-0.24	-0.99	-0.61	0.86	1.0	0.68	0.58	0.76	1.0	0.6	0.27	-0.86	-0.96	0.92	0.86	-0.95	1.0	-0.24

Click cells to compare fundamentals

IO Biotech Account Relationship Matchups

IO Biotech fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	5.7M	222.3M	151.8M	150.7M	67.7M	111.4M
Other Current Liab	2.5M	6.4M	5.6M	11.2M	14.1M	7.5M
Total Current Liabilities	3.1M	10.3M	10.7M	15.7M	19.5M	12.8M
Total Stockholder Equity	(35.3M)	211.9M	138.9M	133.2M	47.0M	86.6M
Net Debt	(3.4M)	(211.5M)	(139.8M)	(140.7M)	(58.1M)	(61.0M)
Retained Earnings	(38.4M)	(106.3M)	(177.7M)	(263.8M)	(359.3M)	(341.3M)
Accounts Payable	522K	3.9M	4.0M	3.9M	4.7M	3.3M
Cash	3.4M	211.5M	142.6M	143.2M	60.0M	104.2M
Non Current Assets Total	18K	550K	3.6M	3.5M	2.7M	1.9M
Non Currrent Assets Other	18K	127K	84K	357K	385K	404.3K
Other Assets	18K	550K	352K	1.0	1.15	1.09
Cash And Short Term Investments	3.4M	211.5M	142.6M	143.2M	60.0M	104.2M
Net Receivables	1.5M	2.1M	1.5M	1.1M	1.0M	1.2M
Liabilities And Stockholders Equity	5.7M	222.3M	151.8M	150.7M	67.7M	111.4M
Non Current Liabilities Total	37.9M	59K	2.3M	1.8M	1.2M	1.1M
Other Current Assets	371K	8.1M	4.1M	2.9M	4.9M	3.8M
Other Stockholder Equity	(36.8M)	319.7M	326.7M	406.6M	413.1M	258.3M
Total Liab	41.0M	10.4M	13.0M	17.6M	20.7M	18.1M
Net Invested Capital	(35.3M)	211.9M	138.9M	133.2M	47.0M	88.1M
Total Current Assets	5.6M	221.7M	148.2M	147.3M	65.0M	109.5M
Accumulated Other Comprehensive Income	2.0M	(1.5M)	(10.1M)	(9.7M)	(6.9M)	(6.5M)
Net Working Capital	2.6M	211.4M	137.5M	131.5M	45.5M	43.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for IOBT Stock Analysis

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC